Related Experiment Video
Updated: May 11, 2025

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges,
Elaine Tomlins1, Helen Winter2, Anna Olsson-Brown3
1Lead Cancer Nurse, Royal Marsden NHS Foundation Trust.
Abstract:
Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...